<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550394</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA</org_study_id>
    <secondary_id>R21AA016372</secondary_id>
    <nct_id>NCT00550394</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults</brief_title>
  <official_title>Quetiapine Plus Topiramate or Placebo for Bipolar Mania &amp; Alcohol Use in Adolescents &amp; Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to study the effects (both good and bad) of combining&#xD;
      quetiapine and topiramate for treating symptoms of bipolar mania (an illness with periods of&#xD;
      elation, excessive excitement, irritability, high energy, racing thoughts, poor sleep, poor&#xD;
      judgment, reckless behavior) and to study the effects (both good and bad) of combining&#xD;
      quetiapine and topiramate for reducing use of alcohol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To collect preliminary data regarding the efficacy and tolerability of&#xD;
      topiramate for the treatment of alcohol use disorders (alcohol abuse and dependence) in&#xD;
      adolescents with bipolar disorder.&#xD;
&#xD;
      Hypothesis 1: We hypothesize that topiramate in combination with quetiapine will lead to&#xD;
      greater reduction in alcohol consumption (number of drinks per day, number of drinks per&#xD;
      drinking day, and number of heavy drinking days) and greater abstinence (percentage of days&#xD;
      abstinent) compared with quetiapine alone.&#xD;
&#xD;
      Specific Aim 2: To obtain preliminary data regarding the efficacy of topiramate for reducing&#xD;
      manic symptoms in adolescents with co-occurring alcohol use and bipolar disorders.&#xD;
&#xD;
      Hypothesis 2: We hypothesize that the topiramate in combination with quetiapine will produce&#xD;
      greater reduction in Young Mania Rating Scale (YMRS) scores than quetiapine alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drinks Per Day</measure>
    <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
    <description>Change in self-reported drinks/day (drinks consumed divided by the number of days during that study period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drinks Per Drinking Day</measure>
    <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
    <description>Change in drinks/drinking day (number of drinks consumed divided by the number of days during which alcohol was consumed during that study period)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Days Abstinent</measure>
    <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
    <description>Change in percent days abstinent (the number of non-drinking days divided by the number of days in that study period).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
    <description>Change in percent heavy drinking days (number of days of &gt; 4 drinks/day divided by number of days in that study period).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Quetiapine and Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quetiapine and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine and Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine and Topiramate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine and placebo</intervention_name>
    <description>Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
    <arm_group_label>Quetiapine and Placebo</arm_group_label>
    <other_name>Quetiapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine and Topiramate</intervention_name>
    <description>Dosing Schedule and Titration of Quetiapine:&#xD;
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
    <arm_group_label>Quetiapine and Topiramate</arm_group_label>
    <other_name>Topiramate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 12-25 years;&#xD;
&#xD;
          2. DSM-IV-TR83 criteria for bipolar disorder, type I, manic or mixed episode;&#xD;
&#xD;
          3. Young Mania Rating Scale (YMRS)86-88 score of &gt; 16 at screening and baseline visits;&#xD;
&#xD;
          4. DSM-IV-TR83 criteria for current alcohol abuse or dependence;&#xD;
&#xD;
          5. Drinking &gt;8 drinks in 30 days within the previous 6 months while meeting DSM-IV&#xD;
             criteria for alcohol abuse or dependence.&#xD;
&#xD;
             One standard drink is defined as 0.35 liters of beer, 0.15 liters of wine, or 0.04&#xD;
             liters of 80-proof liquor;&#xD;
&#xD;
          6. Fluent in English;&#xD;
&#xD;
          7. Provision of written informed consent/assent; 8) If female and of child bearing&#xD;
             potential, agrees to use one of the following method of birth control: complete&#xD;
             abstinence, barrier (diaphragm or condom), or oral contraceptive containing &gt; 35&#xD;
             micrograms of ethinyl estradiol (because concomitant use of topiramate and lower&#xD;
             estrogen oral contraceptives may lead to contraceptive failure).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Manic symptoms resulting from acute medical illness or acute intoxication or&#xD;
             withdrawal from drugs or alcohol as determined by medical evaluation and rapid symptom&#xD;
             resolution;&#xD;
&#xD;
          2. Clinically significant alcohol or drug withdrawal symptoms that have the potential to&#xD;
             cause serious consequences as determined by vital signs, the CIWA-Ar,84 and medical&#xD;
             evaluation;&#xD;
&#xD;
          3. Any unstable medical illness or laboratory abnormalities &gt; 3 times upper limits of&#xD;
             normal;&#xD;
&#xD;
          4. A documented history of mental retardation or an IQ total score &lt; 70 as determined by&#xD;
             the Wechsler Abbreviated Scale of Intelligence (WASI),154 administered by a trained&#xD;
             psychometrician;&#xD;
&#xD;
          5. Any substance use other than alcohol, nicotine, or cannabis during the 30 days prior&#xD;
             to study participation;&#xD;
&#xD;
          6. A positive urine pregnancy test or lactating;&#xD;
&#xD;
          7. History of nephrolithiasis.&#xD;
&#xD;
          8. Treatment with concurrent mood stabilizers, antipsychotics or antidepressants;&#xD;
&#xD;
          9. Treatment with antipsychotics or other mood stabilizers within 72 hours and&#xD;
             antidepressants within 5 days prior to randomization;&#xD;
&#xD;
         10. Treatment with fluoxetine within one month;&#xD;
&#xD;
         11. A history of non-response or hypersensitivity to quetiapine or topiramate;&#xD;
&#xD;
         12. Serious suicidal ideation (&gt; 3 on the CDRS-R89 suicide item, or any serious suicide&#xD;
             attempt within the prior 60 days as judged by the investigator; 3=has thoughts about&#xD;
             suicide or hurting themselves usually when angry);&#xD;
&#xD;
         13. Treatment for substance use during 30 days prior to screening (excluding peer support&#xD;
             groups);&#xD;
&#xD;
         14. Court-ordered to substance use treatment;&#xD;
&#xD;
         15. Acute intoxication;&#xD;
&#xD;
         16. History of a medication change during the prior 30 days that may have precipitated&#xD;
             manic symptoms;&#xD;
&#xD;
         17. History of a partial response (any improvement) to any existing medications as&#xD;
             reported by treating clinician, subjects or legal guardian.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa P DelBello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2007</study_first_posted>
  <results_first_submitted>May 19, 2016</results_first_submitted>
  <results_first_submitted_qc>April 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 23, 2017</results_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Melissa Delbello</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>56 study participants were consented for study participation, of which 17 were screen fails.</recruitment_details>
      <pre_assignment_details>56 study participants were consented for study participation, of which 17 were screen fails.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine and Placebo</title>
          <description>Quetiapine and Placebo&#xD;
quetiapine and placebo: Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
        </group>
        <group group_id="P2">
          <title>Quetiapine and Topiramate</title>
          <description>Quetiapine and Topiramate&#xD;
Quetiapine and Topiramate: Dosing Schedule and Titration of Quetiapine:&#xD;
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quitiapine and Placebo</title>
          <description>Quetiapine and Placebo&#xD;
quetiapine and placebo: Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
        </group>
        <group group_id="B2">
          <title>Quitiapine andTopiramate</title>
          <description>Quetiapine and Topiramate&#xD;
Quetiapine andTopiramate: Dosing Schedule and Titration of Quetiapine:&#xD;
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="3.1"/>
                    <measurement group_id="B2" value="17.7" spread="2.4"/>
                    <measurement group_id="B3" value="17.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drinks Per Day</title>
        <description>Change in self-reported drinks/day (drinks consumed divided by the number of days during that study period).</description>
        <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine + Placebo</title>
            <description>Quetiapine + Placebo&#xD;
quetiapine + placebo: Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine + Topiramate</title>
            <description>Quetiapine + Topiramate&#xD;
Quetiapine + Topiramate: Dosing Schedule and Titration of Quetiapine:&#xD;
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Drinks Per Day</title>
          <description>Change in self-reported drinks/day (drinks consumed divided by the number of days during that study period).</description>
          <units>Drinks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.3"/>
                    <measurement group_id="O2" value="-2.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drinks Per Drinking Day</title>
        <description>Change in drinks/drinking day (number of drinks consumed divided by the number of days during which alcohol was consumed during that study period)</description>
        <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine and Placebo</title>
            <description>Quetiapine and Placebo</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine and Topiramate</title>
            <description>Quetiapine and Topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Drinks Per Drinking Day</title>
          <description>Change in drinks/drinking day (number of drinks consumed divided by the number of days during which alcohol was consumed during that study period)</description>
          <units>Drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="10.2"/>
                    <measurement group_id="O2" value="-7.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days Abstinent</title>
        <description>Change in percent days abstinent (the number of non-drinking days divided by the number of days in that study period).</description>
        <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine and Placebo</title>
            <description>Quetiapine and Placebo</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine and Topiramate</title>
            <description>Quetiapine and Topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days Abstinent</title>
          <description>Change in percent days abstinent (the number of non-drinking days divided by the number of days in that study period).</description>
          <units>Percentage of days abstinent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="19"/>
                    <measurement group_id="O2" value="14" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>Change in percent heavy drinking days (number of days of &gt; 4 drinks/day divided by number of days in that study period).</description>
        <time_frame>baseline to 12 weeks or endpoint (up to 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine and Placebo</title>
            <description>Quetiapine and Placebo</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine and Topiramate</title>
            <description>Quetiapine and Topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days</title>
          <description>Change in percent heavy drinking days (number of days of &gt; 4 drinks/day divided by number of days in that study period).</description>
          <units>Percent heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="19"/>
                    <measurement group_id="O2" value="-14" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years 9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine and Placebo</title>
          <description>Quetiapine and Placebo&#xD;
quetiapine + placebo: Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
        </group>
        <group group_id="E2">
          <title>Quetiapine and Topiramate</title>
          <description>Quetiapine and Topiramate&#xD;
Quetiapine + Topiramate: Dosing Schedule and Titration of Quetiapine:&#xD;
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1&#xD;
Dosing Schedule and Titration of Topiramate:&#xD;
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.&#xD;
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Difficulty Arousing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Additional studies are needed as topiramate has not been systematically assessed. This study was to collect pilot data and more data will need to be collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Melissa DelBello, MD, MS</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-2989</phone>
      <email>delbelmp@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

